Companies › Kamau Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| nula-cel Gene correction therapy - autologous CD34+ hematopoietic stem cells with HbS to HbA gene c | – | Phase 1 | Sickle Cell Disease | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04819841 | nula-cel | Phase 1 | Sickle Cell Disease | Hematology | Dec 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.